FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107129971> ?p ?o ?g. }

• W2107129971 endingPage "630" @default.
• W2107129971 startingPage "623" @default.
• W2107129971 abstract "Tacrolimus has proven to be a potent immunosuppressive agent in liver transplantation (LT). Its introduction has led to significantly less frequent and severe acute rejection. Little is known about the rate of chronic rejection (CR) in primary LT using tacrolimus therapy. The aim of the present study is to examine the long-term incidence of CR, risk factors, prognostic factors, and outcome after CR. The present study evaluated the development of CR in 1,048 consecutive adult primary liver allograft recipients initiated and mostly maintained on tacrolimus-based immunosuppressive therapy. They were evaluated with a mean follow-up of 77.3 +/- 14.7 months (range, 50.7 to 100.1 months). To assess the impact of primary diagnosis on the rate and outcome of CR, the population was divided into 3 groups. Group I included patients with hepatitis C virus (HCV)- or hepatitis B virus (HBV)-induced cirrhosis (n = 312); group II included patients diagnosed with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), or autoimmune hepatitis (AIH; n = 217); and group III included patients with all other diagnoses (n = 519). Overall, 32 of 1,048 patients (3.1%) developed CR. This represented 13 (4.1%), 12 (5.5%), and 7 patients (1.3%) in groups I, II, and III, respectively. The relative risk for developing CR was 3.2 times greater for group I and 4.3 times greater for group II compared with group III. This difference was statistically significant (P =.004). The incidence of acute rejection and total number of acute rejection episodes were significantly greater in patients who developed CR compared with those who did not (P <.0001). Similarly, the mean donor age for CR was significantly older than for patients without CR (43.0 v 36.2 years; P =.02). Thirteen of the 32 patients (40.6%) who developed CR retained their original grafts for a mean period of 54 +/- 25 months after diagnosis. Seven patients (21.9%) underwent re-LT, and 12 patients (38.3%) died. Serum bilirubin levels and the presence of arteriopathy, arterial loss, and duct loss on liver biopsy at the time of diagnosis of CR were significantly greater among the 3 groups of patients. In addition, patient and graft survival for group I were significantly worse compared with groups II and III. We conclude that CR occurred rarely among patients maintained long term on tacrolimus-based immunosuppressive therapy. When steroid use is controlled, the incidence of acute rejection, mean donor age, HBV- and/or HCV-induced cirrhosis, or a diagnosis of PBC, PSC, or AIH were found to be predictors of CR. Greater values for serum bilirubin level, duct loss, arteriopathy, arteriolar loss, and presence of HCV or HBV were found to be poor prognostic factors for the 3 groups; greater total serum bilirubin value (P =.05) was the only factor found to be significant between patients who had graft loss versus those who recovered." @default.
• W2107129971 created "2016-06-24" @default.
• W2107129971 creator A5007117355 @default.
• W2107129971 creator A5007266246 @default.
• W2107129971 creator A5022963653 @default.
• W2107129971 creator A5029756384 @default.
• W2107129971 creator A5029854179 @default.
• W2107129971 creator A5033912938 @default.
• W2107129971 creator A5071920088 @default.
• W2107129971 creator A5078128536 @default.
• W2107129971 creator A5081289232 @default.
• W2107129971 date "2001-07-01" @default.
• W2107129971 modified "2023-09-26" @default.
• W2107129971 title "Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years" @default.
• W2107129971 cites W14158944 @default.
• W2107129971 cites W1458946433 @default.
• W2107129971 cites W1481545258 @default.
• W2107129971 cites W1561127284 @default.
• W2107129971 cites W1573393476 @default.
• W2107129971 cites W1585321597 @default.
• W2107129971 cites W1601514034 @default.
• W2107129971 cites W162364532 @default.
• W2107129971 cites W1971051442 @default.
• W2107129971 cites W1971845349 @default.
• W2107129971 cites W1985423921 @default.
• W2107129971 cites W1987166713 @default.
• W2107129971 cites W1987377262 @default.
• W2107129971 cites W1988691018 @default.
• W2107129971 cites W1989889912 @default.
• W2107129971 cites W1992619786 @default.
• W2107129971 cites W2001369313 @default.
• W2107129971 cites W2006937499 @default.
• W2107129971 cites W2008229425 @default.
• W2107129971 cites W2009256994 @default.
• W2107129971 cites W2020329640 @default.
• W2107129971 cites W2022444135 @default.
• W2107129971 cites W2023878686 @default.
• W2107129971 cites W2026881780 @default.
• W2107129971 cites W2028872302 @default.
• W2107129971 cites W2034683890 @default.
• W2107129971 cites W2040349032 @default.
• W2107129971 cites W2044423148 @default.
• W2107129971 cites W205753852 @default.
• W2107129971 cites W2059396994 @default.
• W2107129971 cites W2060131336 @default.
• W2107129971 cites W2065821192 @default.
• W2107129971 cites W2067194028 @default.
• W2107129971 cites W2074261174 @default.
• W2107129971 cites W2084751994 @default.
• W2107129971 cites W2087470352 @default.
• W2107129971 cites W2090293261 @default.
• W2107129971 cites W2106736247 @default.
• W2107129971 cites W2111649100 @default.
• W2107129971 cites W2124128143 @default.
• W2107129971 cites W2147077869 @default.
• W2107129971 cites W2164482108 @default.
• W2107129971 cites W2322379352 @default.
• W2107129971 cites W23832122 @default.
• W2107129971 cites W2395813523 @default.
• W2107129971 cites W2404730302 @default.
• W2107129971 cites W2406552808 @default.
• W2107129971 cites W2407771587 @default.
• W2107129971 cites W2410811185 @default.
• W2107129971 cites W2412044965 @default.
• W2107129971 cites W301732727 @default.
• W2107129971 cites W4205363739 @default.
• W2107129971 cites W4298150640 @default.
• W2107129971 cites W4301380634 @default.
• W2107129971 cites W67194915 @default.
• W2107129971 doi "https://doi.org/10.1053/jlts.2001.25364" @default.
• W2107129971 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2965463" @default.
• W2107129971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11460230" @default.
• W2107129971 hasPublicationYear "2001" @default.
• W2107129971 type Work @default.
• W2107129971 sameAs 2107129971 @default.
• W2107129971 citedByCount "77" @default.
• W2107129971 countsByYear W21071299712012 @default.
• W2107129971 countsByYear W21071299712014 @default.
• W2107129971 countsByYear W21071299712015 @default.
• W2107129971 countsByYear W21071299712016 @default.
• W2107129971 countsByYear W21071299712017 @default.
• W2107129971 countsByYear W21071299712018 @default.
• W2107129971 countsByYear W21071299712019 @default.
• W2107129971 countsByYear W21071299712020 @default.
• W2107129971 countsByYear W21071299712021 @default.
• W2107129971 countsByYear W21071299712022 @default.
• W2107129971 countsByYear W21071299712023 @default.
• W2107129971 crossrefType "journal-article" @default.
• W2107129971 hasAuthorship W2107129971A5007117355 @default.
• W2107129971 hasAuthorship W2107129971A5007266246 @default.
• W2107129971 hasAuthorship W2107129971A5022963653 @default.
• W2107129971 hasAuthorship W2107129971A5029756384 @default.
• W2107129971 hasAuthorship W2107129971A5029854179 @default.
• W2107129971 hasAuthorship W2107129971A5033912938 @default.
• W2107129971 hasAuthorship W2107129971A5071920088 @default.
• W2107129971 hasAuthorship W2107129971A5078128536 @default.
• W2107129971 hasAuthorship W2107129971A5081289232 @default.
• W2107129971 hasBestOaLocation W21071299711 @default.

• next